

QUANTUM HEALTHCARE LIMITED
(Company Registration No. 202218645W)
(Incorporated in Singapore)

EARNINGS GUIDANCE FOR THE SIX MONTHS ENDED 30 JUNE 2024

The Board of Directors ("**Directors**" or "**Board**") of Quantum Healthcare Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to announce that the Group is expecting to report a narrowing loss for the six months ended 30 June 2024 ("**HY2024**") as compared to the six months ended 30 June 2023 ("**HY2023**"). The earnings guidance is based on a preliminary assessment of the Group's unaudited consolidated financial results for HY2024.

The anticipated reduction in net loss for HY2024 is mainly attributed to the gain from disposal of 11% of the Company's shareholdings in its subsidiary, Asia Dental Group Pte Ltd and a decrease in administrative expenses primarily driven by significant legal expenses incurred in HY2023 for the arbitration involving TriReme Singapore Pte Ltd and Quattro Vascular Pte Ltd and InnoRa GmbH. These expenses were non-operating and one-off in nature. The Group did not incur any additional legal fees for the arbitration in HY2024. The reduction in net loss was offset by a decrease in gross profit of the healthcare business segment due to slowdown in business activities.

The Company is in the process of finalising the Group's unaudited consolidated financial results for HY2024 which will be announced on or before 14 August 2024. Shareholders and potential investors are advised to read the Group's HY2024 results announcement in their entirety once they are published on SGXNet.

In the meantime, shareholders and investors are advised to exercise caution when dealing in the Company's shares. When in doubt, shareholders and potential investors are advised to seek independent advice from their professional advisors before trading or making any investment decision on the Company's shares.

By Order of the Board of Directors

QUANTUM HEALTHCARE LIMITED

Thomas Tan Gim Chua
Chief Executive Officer and Executive Director
6 August 2024

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.